The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia.
The new fund, announced Thursday by Arie Belldegrun's Vida Ventures, brings the total amount of money raised to approximately $1 billion.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
A New York City Health Business Leaders report details the top 12 healthcare financings of the second quarter, including investments in organizations like RubiconMD, Kronos Bio and Thrive Global.
Assuming all goes well, potential prostate cancer drug candidate could enter clinic by end of next year, Norbert Bischofberger says.